Dyax Corp. (DYAX) Release: KALBITOR® (ecallantide) Data in HAE Presented at the Dyax Corp. (DYAX) Annual Meeting
11/7/2011 6:57:07 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that two oral and two poster presentations featuring KALBITOR® (ecallantide) data in hereditary angioedema (HAE) were presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held November 3-8, at the Hynes Convention Center in Boston, MA. Three of the presentations featured results from patients enrolled in DX-88/19, an open-label continuation study of ecallantide for the treatment of acute HAE attacks, and the fourth highlighted integrated results from 2 double-blind, placebo-controlled studies of ecallantide for treatment of acute HAE attacks, the EDEMA3® and EDEMA4® studies. KALBITOR® is indicated for the treatment of acute attacks of HAE in patients 16 years of age and older.